GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » PS Ratio

Zogenix (Zogenix) PS Ratio : 18.26 (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zogenix's share price is $26.68. Zogenix's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $1.46. Hence, Zogenix's PS Ratio for today is 18.26.

The historical rank and industry rank for Zogenix's PS Ratio or its related term are showing as below:

ZGNX' s PS Ratio Range Over the Past 10 Years
Min: 0.56   Med: 11.21   Max: 2000.4
Current: 18.26

During the past 13 years, Zogenix's highest PS Ratio was 2000.40. The lowest was 0.56. And the median was 11.21.

ZGNX's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.145 vs ZGNX: 18.26

Zogenix's Revenue per Sharefor the three months ended in Dec. 2021 was $0.48. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $1.46.

During the past 12 months, the average Revenue per Share Growth Rate of Zogenix was 475.60% per year.

During the past 13 years, Zogenix's highest 3-Year average Revenue per Share Growth Rate was -11.00% per year. The lowest was 0.00% per year. And the median was -39.10% per year.

Back to Basics: PS Ratio


Zogenix PS Ratio Historical Data

The historical data trend for Zogenix's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix PS Ratio Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 111.25 - 613.29 78.70 11.11

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.70 41.71 21.98 13.34 11.11

Competitive Comparison of Zogenix's PS Ratio

For the Biotechnology subindustry, Zogenix's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zogenix's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's PS Ratio distribution charts can be found below:

* The bar in red indicates where Zogenix's PS Ratio falls into.



Zogenix PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Zogenix's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=26.68/1.461
=18.26

Zogenix's Share Price of today is $26.68.
Zogenix's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.46.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Zogenix  (NAS:ZGNX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Zogenix PS Ratio Related Terms

Thank you for viewing the detailed overview of Zogenix's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5

Zogenix (Zogenix) Headlines

From GuruFocus

UCB Completes Acquisition of Zogenix, Inc.

By PRNewswire PRNewswire 03-07-2022

Zogenix Reports Granting of Inducement Awards

By Marketwired Marketwired 10-19-2021

Zogenix Reports Granting of Inducement Awards

By GlobeNewswire GlobeNewswire 09-16-2021